NightstaRx initiates Phase I/II trial of AAV-XLRPGR therapy to treat XLRP

UK-based biopharmaceutical company NightstaRx (Nightstar) has initiated enrolment and dosing in a Phase I/II clinical trial of its gene therapy 'AAV- XLRPGR' for the treatment of patients with X-linked retinitis pigmentosa (XLRP).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news